Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financi...(taxes payable 30...)

Date:3/26/2009

taxes payable 3,085 130 Net cash provided by operating activities 12,629 1,563 Cash flows from investing activities Advances to related parties (19) (876) Proceeds from collection of advances to related parties 657 262 Purchase of property and equipment (638) (64) Purchase of product rights (2,450) (75) Collection of deposits 223 50 Payment of deposits (237) (15) Cash acquired in connection with the Merger, net of costs paid 2,118 - Net cash used in investing activities (346) (718) Cash flows from financing activities Principal payments on license agreement liability $(576) $(720) Proceeds from line of credit 7,250 9,000 Principal payments on line of credit (9,000) (9,000) Principal payments on related party note payable (460) - Exercise of common stock warrants 52 - Payment of stock issuance costs in connection with the Merger (504) - Net cash used in financing activities (3,238) (720) Net increase in cash and cash equivalents 9,045 125 Cash and cash equivalents as of beginning of year 241 116 Cash and cash equivalents as of end of year 9,286 241 Supplemental disclosure of cash flow information Cash paid during the year for interest 2,734 433 Cash paid during the year for income taxes $644
'/>"/>

SOURCE Cornerstone Therapeutics Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related biology technology :

1. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
2. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
3. Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders
4. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Tuesday, March 24, 2009
5. Cell Therapeutics Announces Filing of Form 10-K
6. Horizon Therapeutics Selected to Present at InsideVentures Debut Investor Conference March 25-26, Santa Barbara, California
7. Oxygen Biotherapeutics, Inc. Expands Board of Directors
8. Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics
9. Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference
10. Nile Therapeutics Announces Information in Compliance With NASDAQ Marketplace Rule 4350 and Reiterates 2009 Objectives
11. Medarex to Present at the Needham Cancer Therapeutics Conference